GoldenGolden
Novavax

Novavax

Clinical stage biotechnology company focused on treating infectious diseases using recombinant nanoparticle vaccine technology

Novovax is a clinical stage biotechnology company focused on treating infectious diseases using recombinant nanoparticle vaccine technology. The company’s vaccine candidates are genetically engineered three-dimensional nanostructures that incorporate recombinant proteins that are critical to disease pathogenesis.

Novovirus generates their vaccine nanoparticles in insect cells. Cells of the fall armyworm, Spodoptera frugiperda, are grown as a cell line called Sf9. When infected with baculovirus, they have can continue to multiply indefinitely. The baculovirus is engineered to carry foreign genes to program the Sf9 cells to produce desired proteins. Recombinant proteins are designed to self-assemble into nanoparticle constructs in such a way as to elicit a strong immune response.

Novavax’s lead product is a nanoparticle flu vaccine called NanoFlu. The company developed vaccines for SARS and Middle East respiratory syndrome, that have not received regulatory approval. Novavax developed a RSV (respiratory syncytial virus) vaccine called ResVax that failed in two late-stage clinical studies. Novavax is working on a vaccine for the new coronavirus responsible for the COVID-19 outbreak.

Timeline

June 14, 2021
Novavax announces that it had completed a large efficacy trial of its COVID-19 vaccine.
May 21, 2021
Novavax announces that it receives 'Life Sciences Company of the Year' award from Maryland Tech Council.
April 13, 2021
Novavax announces promotion of Gale E. Smith, Ph.D to senior vice president and chief scientist in Discovery and Pre-clinical Reseach.
January 28, 2021
An experimental coronavirus vaccine developed by Novavax is 89.3 percent effective at preventing Covid-19.

Moderna announced this week that its vaccine appears to be less effective against the South African variant, although it said protective antibodies remained above protective levels.

November 9, 2020
Novavax appoints Gregory F. Covino as Chief Financial Officer.
July 7, 2020
Novavax raises a $1,600,000,000 grant.
June 15, 2020
Novavax raises a $200,000,000 private equity from RA Capital Management.
May 26, 2020
Novavax announces it received $384 million from CEPI.
May 11, 2020
Novavax raises a $384,000,000 grant from Coalition for Epidemic Preparedness Innovations.
March 10, 2020
Novavax raises a $4,000,000 grant from Coalition for Epidemic Preparedness Innovations.
Page 1 of 2

Funding rounds

People

Name
Role
LinkedIn

Gregory Glenn, MD

President of Research and Development

Further reading

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Robin Lloyd
June 18, 2021
Scientific American
Scientific American is the essential guide to the most awe-inspiring advances in science and technology, explaining how they change our understanding of the world and shape our lives.
Novavax, Inc.
June 17, 2021
www.prnewswire.com:443
/PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that...
ANI
June 17, 2021
@bsindia
Novavaxs vaccine candidate has partnered with Pune-based vaccine manufacturer Serum Institute of India to produce doses in India.
Novavax, Inc.
June 17, 2021
www.prnewswire.com:443
/PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that...
June 16, 2021
Moneycontrol
In September 2020, Novavax had announced a manufacturing agreement with the Serum Institute of India for its COVID-19 vaccine candidate NVX-CoV2373.
Divya Rajagopal
June 16, 2021
mint
SII is unlikely to launch jab by September due to delay in receiving bioreactor bags, enzymes
Andrew Dunn
June 16, 2021
news.yahoo.com
CureVac's stock tanked after the announcement. The German biotech blamed variants in a press release.
Special Correspondent
June 15, 2021
The Hindu
AY.1 found in Andhra Pradesh, Maharashtra, Telangana and Karnataka
Novavax, Inc.
June 15, 2021
www.prnewswire.com:443
/PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a annoncé aujourd'hui que NVX-CoV2373, son vaccin recombinant à base de nanoparticules protéiques contre la...
Novavax, Inc.
June 15, 2021
www.prnewswire.com:443
/PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), hat heute bekannt gegeben, dass NVX-CoV2373, sein rekombinanter COVID-19-Impfstoff auf der Basis von...
Livemint
June 15, 2021
mint
In the 29,960-person trial, the two-shot inoculation was 90% effective at preventing symptomatic Covid and 100% effective at preventing moderate and severe symptoms,
Richard Willingham
June 15, 2021
www.abc.net.au
Documents show the Victorian government said changing suppliers would lead to cost blowouts and delays.
ABC News
June 15, 2021
www.abc.net.au
More than 1,000 people flock to the KwaZulu-Natal province in South Africa in search of diamonds.
Antonette Collins
June 15, 2021
www.abc.net.au
Construction on Sydney's newest city centre will begin before the end of the year, with the NSW government releasing first images of how it will look.
Novavax, Inc.
June 15, 2021
www.prnewswire.com:443
/PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), anunció hoy que NVX-CoV2373, su vacuna recombinante basada en proteínas de nanopartículas contra la COVID-19...
Novavax, Inc.
June 15, 2021
www.prnewswire.com:443
/PRNewswire/ -- A Novavax, Inc. (Nasdaq: NVAX) anunciou hoje que a NVX-CoV2373, sua vacina contra a COVID-19, à base de proteína recombinante e nanopartículas,...
John Timmer
June 14, 2021
Ars Technica
While not needed for the US, it should help with the global vaccine push.
Novavax, Inc.
June 14, 2021
www.prnewswire.com:443
/PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced data...
Novavax, Inc.
June 14, 2021
www.prnewswire.com:443
-La vacuna de Novavax para la COVID-19 demuestra una eficacia global del 90% y una protección del 100% contra la enfermedad moderada y grave en el ensayo de...
Brandon May
June 14, 2021
BioSpace
The study also found the vaccine was 100% effective at preventing moderate and severe disease.
SHOW MORE

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.